Corcept Therapeutics (CORT) Share-based Compensation (2010 - 2026)

Corcept Therapeutics has disclosed Share-based Compensation across 17 years of filings, most recently posting $23.0 million for Q1 2026.

• Share-based Compensation for Q1 2026 came in at $23.0 million, up 5.56% year-over-year; the trailing twelve-month figure through Mar 2026 was $85.7 million (up 22.56% YoY), and the FY2025 annual result was $84.5 million, up 37.73% from the prior year.
• Share-based Compensation came in at $23.0 million for Q1 2026 at Corcept Therapeutics, up from $20.8 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $23.0 million in Q1 2026 to a low of $10.5 million in Q4 2022.
• The 5-year median for Share-based Compensation is $13.2 million (2024), against an average of $15.3 million.
• Across the five-year window, Share-based Compensation decreased 4.17% in 2022 and surged 64.77% in 2025, its largest moves.
• Corcept Therapeutics' Share-based Compensation stood at $10.5 million in 2022, then grew by 24.18% to $13.1 million in 2023, then advanced by 28.56% to $16.8 million in 2024, then climbed by 23.65% to $20.8 million in 2025, then grew by 10.95% to $23.0 million in 2026.
• The last three Share-based Compensation figures came in at $23.0 million (Q1 2026), $20.8 million (Q4 2025), and $22.9 million (Q3 2025), per Business Quant data.